SNGX News and Press, Soligenix Inc. From 06/07/22

Strategy supports global need and has potential use in growing home healthcare market New York, New York--(Newsfile Corp. - June 7, 2022) - PCG Digital -- Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and com...

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board o...

Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified PR Newswire Paper published in the Journal Structure PRINCETON, N.J. , June 1, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Compan...

The clinical-stage biotech Soligenix (NASDAQ:SNGX) is trading higher for the third straight session on Monday after indicating the potential to secure a U.S. patent covering its thermostabilized vaccine platform. The company said that the United States Patent and Trademark Office (USPTO) issu...

Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform PR Newswire Includes thermostabilized Ebola vaccines Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON , N.J. , May 23, 2022 /PRNews...

Soligenix to Present at the H.C. Wainwright Global Investment Conference PR Newswire PRINCETON, N.J. , May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and...

Soligenix press release (NASDAQ:SNGX): Q1 GAAP EPS of -$0.10 misses by $0.03. Revenue of $0.2M (+100.0% Y/Y) beats by $0.1M. For further details see: Soligenix GAAP EPS of -$0.10 misses by $0.03, revenue of $0.2M beats by $0.1M

Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results PR Newswire PRINCETON, N.J. , May 13, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on dev...

Soligenix Receives $1.4M in Non-Dilutive Government Funding PR Newswire PRINCETON, N.J. , April 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commer...

Soligenix press release (NASDAQ:SNGX): FY GAAP EPS of -$0.31 misses by $0.01. Revenue of $0.8M (-66.7% Y/Y) beats by $0.08M. As of December 31, 2021, the Company's cash position was approximately $26.0M. For further details see: Soligenix GAAP EPS of -$0.31 misses by $0.01, revenue of $...